Orica-GreenEdge take responsibility for Simon Yates' positive test

Australian team says doctor who supplied Yates with Asthma medication failed to apply for a Therapeutic Use Exemption

19 July 2014
101st Tour de France
Stage 14 : Grenoble - Risoul
YATES Simon (GBR) Orica - GreenEDGE
Photo : Yuzuru SUNADA

(Image credit: Yuzuru SUNADA)

Orica-GreenEdge have taken responsibility for Simon Yates' positive test, which they confirmed was for the substance Terbutaline and was discovered during an in-competition test on stage six of the 2016 Paris-Nice.

The Australian team said that the substance, which is used as a reliever for symptoms of asthma, was properly administered by a team doctor in the form of an inhaler, but a Therapeutic Use Exemption (TUE) was not obtained from the UCI.

Thank you for reading 20 articles this month* Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read 5 free articles per month without a subscription

Join now for unlimited access

Try first month for just £1 / $1 / €1

Richard Windsor

Follow on Twitter: @richwindy

Richard is digital editor of Cycling Weekly. Joining the team in 2013, Richard became editor of the website in 2014 and coordinates site content and strategy, leading the news team in coverage of the world's biggest races and working with the tech editor to deliver comprehensive buying guides, reviews, and the latest product news.

An occasional racer, Richard spends most of his time preparing for long-distance touring rides these days, or getting out to the Surrey Hills on the weekend on his Specialized Tarmac SL6 (with an obligatory pub stop of course).